These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 6961973)

  • 41. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
    Adler A; Altbaum I
    J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of hyperthermia in regional alkylating agent chemotherapy.
    Abdel-Wahab OI; Grubbs E; Viglianti BL; Cheng TY; Ueno T; Ko S; Rabbani Z; Curtis S; Pruitt SK; Dewhirst MW; Tyler DS
    Clin Cancer Res; 2004 Sep; 10(17):5919-29. PubMed ID: 15355925
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Experience in the preparation and experimental use of immunocytostatics.
    Embleton MJ; Pimm MV; Garnett MC; Rowland GF; Simmonds RG; Baldwin RW
    Behring Inst Mitt; 1984 May; (74):108-12. PubMed ID: 6591915
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The efficacy of abraxane on osteosarcoma xenografts in nude mice and expression of secreted protein, acidic and rich in cysteine.
    Yang Y; Niu X; Zhang Q; Hao L; Ding Y; Xu H
    Am J Med Sci; 2012 Sep; 344(3):199-205. PubMed ID: 22222334
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antitumor activity of interferon against murine osteogenic sarcoma in vitro and in vivo.
    Glasgow LA; Crane JL; Kern ER; Youngner JS
    Cancer Treat Rep; 1978 Nov; 62(11):1881-8. PubMed ID: 282006
    [TBL] [Abstract][Full Text] [Related]  

  • 46. cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.
    Schabel FM; Trader MW; Laster WR; Corbett TH; Griswold DP
    Cancer Treat Rep; 1979; 63(9-10):1459-73. PubMed ID: 291480
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 7-substituted actinomycin D analogs. Chemical and growth-inhibitory studies.
    Sengupta SK; Tinter SK; Lazarus H; Brown BL; Modest EJ
    J Med Chem; 1975 Dec; 18(12):1175-80. PubMed ID: 1059773
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.
    Thompson J; George EO; Poquette CA; Cheshire PJ; Richmond LB; de Graaf SS; Ma M; Stewart CF; Houghton PJ
    Clin Cancer Res; 1999 Nov; 5(11):3617-31. PubMed ID: 10589779
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Transplantability of sarcoma 298 following a single administration of sarcolysine].
    Merkulov MF; Talipov ASh
    Farmakol Toksikol; 1971; 34(6):725-8. PubMed ID: 5139798
    [No Abstract]   [Full Text] [Related]  

  • 50. Effect of alanine, glycine, phenylalanine, and tryptophan mustards on Ehrlich ascites carcinoma and Ridgway osteogenic sarcoma.
    Schmid FA; Stern BR; Schmid MM; Tarnowski GS
    Cancer Chemother Rep; 1965 Dec; 49():1-7. PubMed ID: 5216232
    [No Abstract]   [Full Text] [Related]  

  • 51. Xenografts in pharmacologically immunosuppressed mice as a model to test the chemotherapeutic sensitivity of human tumors.
    Floersheim GL; Bieri A; Chiodetti N
    Int J Cancer; 1986 Jan; 37(1):109-14. PubMed ID: 3455687
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Isolated limb perfusion with melphalan, tumour necrosis factor-alpha and oncolytic vaccinia virus improves tumour targeting and prolongs survival in a rat model of advanced extremity sarcoma.
    Pencavel TD; Wilkinson MJ; Mansfield DC; Khan AA; Seth R; Karapanagiotou EM; Roulstone V; Aguilar RJ; Chen NG; Szalay AA; Hayes AJ; Harrington KJ
    Int J Cancer; 2015 Feb; 136(4):965-76. PubMed ID: 24978211
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma.
    Rosen G; Murphy ML; Huvos AG; Gutierrez M; Marcove RC
    Cancer; 1976 Jan; 37(1):1-11. PubMed ID: 1082364
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Acute in vivo resistance in high-dose therapy.
    Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
    Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The αVβ3/αVβ5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model.
    Ten Hagen TL; Seynhaeve AL; de Wiel-Ambagtsheer Ga; de Bruijn EA; van Tiel ST; Ruegg C; Meyring M; Grell M; Goodman SL; Eggermont AM
    Int J Cancer; 2013 Jun; 132(11):2694-704. PubMed ID: 23152080
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Osteogenic sarcoma: state of the art with high-dose methotrexate treatment.
    Jaffe N
    Clin Orthop Relat Res; 1976 Oct; (120):95-102. PubMed ID: 1086179
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Effect of sarcolysin on H3-thymidine incorporation in loose connective tissue cells of mice with sarcoma 298 and adenocarcinoma 755].
    Rozenberg IB; Iushkov SF
    Farmakol Toksikol; 1972; 35(1):79-84. PubMed ID: 5011524
    [No Abstract]   [Full Text] [Related]  

  • 58. Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy.
    Griswold DP; Trader MW; Frei E; Peters WP; Wolpert MK; Laster WR
    Cancer Res; 1987 May; 47(9):2323-7. PubMed ID: 3567926
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Complete regression of osteogenic sarcoma scalp metastases following one pulse of high-dose melphalan combined with a bone marrow autograft: case report.
    Mauger DC
    N Z Med J; 1982 Jul; 95(711):455-6. PubMed ID: 7050786
    [No Abstract]   [Full Text] [Related]  

  • 60. [Therapy of malignant tumors through the internist].
    Schreml W; Kubanek B
    Aktuelle Probl Chir Orthop; 1977; 5():113-29. PubMed ID: 73352
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.